Clinical characteristics of different histologic types of breast cancer by Li, C I et al.
Clinical characteristics of different histologic types of breast cancer
CI Li*,1, DJ Uribe
1 and JR Daling
1
1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-C308, PO Box 19024, Seattle,
WA 98109-1024, USA
Breast cancer is a heterogeneous disease, though little is known about some of its rarer forms, including certain histologic types. Using
Surveillance, Epidemiology, and End Results Program data on 135157 invasive breast cancer cases diagnosed from 1992 to 2001,
relationships between nine histologic types of breast cancer and various tumour characteristics were assessed. Among women aged
50–89 years at diagnosis, lobular and ductal/lobular carcinoma cases were more likely to be diagnosed with stage III/IV, X5.0cm, and
node-positive tumours compared to ductal carcinoma cases. Mucinous, comedo, tubular, and medullary carcinomas were less likely
to present at an advanced stage. Lobular, ductal/lobular, mucinous, tubular, and papillary carcinomas were less likely, and comedo,
medullary, and inflammatory carcinomas were more likely to be oestrogen receptor (ER) negative/progesterone receptor (PR)
negative and high grade (notably, 68.2% of medullary carcinomas were ER /PR  vs 19.3% of ductal carcinomas). In general, similar
differences were observed among women diagnosed at age 30–49 years. Inflammatory carcinomas are associated with more
aggressive tumour phenotypes, and mucinous, tubular, and papillary tumours are associated with less aggressive phenotypes. The
histologic types of breast cancer studied here differ greatly in their clinical presentations, and the differences in their hormone
receptor profiles and grades point to their likely different aetiologies.
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Although breast cancer remains the most commonly diagnosed
cancer among women in the United States (US) and worldwide,
it is a heterogeneous disease. Breast cancer can be categorized in
several ways, including based on its clinical features, its expression
of tumour markers, and its histologic type. The two most common
histologic types of invasive breast cancer are ductal and lobular
carcinomas, accounting for approximately 75 and 15% of all
cases in the US, respectively (Li et al, 2003a). Interest in lobular
carcinoma in particular has recently been piqued by data
indicating that incidence rates of lobular carcinoma are increasing
more rapidly than are rates of ductal carcinoma in the US.
Specifically, lobular rates have increased by 65% from 1987 to
1999, while rates of ductal carcinoma have increased only by 3%
(Li et al, 2003a). Studies also suggest that lobular carcinomas
are more likely than ductal carcinomas to be hormone receptor
positive (Arpino et al, 2004; Korhonen et al, 2004). This
difference may partly explain why seven studies have consistently
observed that combined oestrogen and progestin postmenopausal
hormone use is more strongly related to lobular carcinoma risk
than to ductal carcinoma risk (Li et al, 2000, 2003b; Chen et al,
2002; Newcomb et al, 2002; Daling et al, 2003; Newcomer et al,
2003).
While several studies have now examined the clinical, patholo-
gic, and epidemiologic differences between ductal and lobular
carcinomas, much less is known about the rarer histologic types of
breast cancer, including mucinous, tubular, comedo, inflamma-
tory, medullary, and papillary carcinomas, which together account
for about 10% of all cases. The purpose of this study is to
characterise how rare histologic types of breast cancer differ in
their stage, size, lymph node status, oestrogen receptor (ER)/PR
status, and grade, utilizing data from 11 population-based tumour
registries that participate in the Surveillance, Epidemiology, and
End Results (SEER) Program. Evaluations of these differences are
important for furthering our understanding of the nature of these
tumours and may provide insight into the aetiologies and clinical
features of different types of breast cancer.
MATERIALS AND METHODS
Women diagnosed with a first primary invasive breast cancer at
30–89 years of age between January 1992 and December 2001 were
identified through 11 population-based cancer registries in the US
that participate in the National Cancer Institute’s SEER Program.
This age range was chosen because the vast majority of breast
cancers diagnosed in the US occur among women in this age
range (498% based on the SEER data used here). Also, different
aetiologic factors likely influence breast cancer occurrence among
women younger than 30 or older than 90 years of age, but since too
few women are diagnosed in these age ranges we could not assess
them separately. The SEER registries that were used include those
serving the states of Connecticut, Hawaii, Iowa, New Mexico, and
Utah, and the urban areas surrounding Atlanta, GA; Detroit, MI;
Los Angeles, CA; San Francisco-Oakland, CA; San Jose-Monterey,
CA; and Seattle, WA. The standard for ascertainment of cases of
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and End Results, National Cancer Institute, 2005a). Individual
patient medical records are the source of SEER data on patient
and tumour characteristics. In general, the populations covered
by SEER are representative of the whole US with regard to
socioeconomic status and education level, though they include
higher proportions of people living in urban areas and who are
foreign born (Surveillance Epidemiology and End Results,
National Cancer Institute, 2005b). Further operational details and
methods used by the SEER Program are provided elsewhere
(Young Jr et al, 1981).
In all, 199721 women 30–89 years of age whose invasive breast
cancer diagnosis was their first primary cancer diagnosis of any
type were eligible for this study. Also, 539 women whose cancers
were either not microscopically confirmed or were diagnosed only
at autopsy were excluded. Women were grouped into the following
nine histologic categories based on the ICD-O-3 code assigned
to their tumours using an approach that has been previously
published (Li et al, 2003c): ductal (defined using ICD-O code
8500), lobular (8520), ductal/lobular (8522), mucinous (8480),
tubular (8211), comedocarcinoma (8501), inflammatory (8530),
medullary (8510), and papillary (8050 and 8503). In addition,
SEER’s Extent of Disease (EOD) codes were used to identify
additional inflammatory cases, since SEER EOD code 70 is used
to define ‘inflammatory carcinoma, including diffuse (beyond
that directly overlying the tumour) dermal lymphatic permeation
or infiltration’. Hence, cases with a SEER EOD code of 70 were
defined as inflammatory, regardless of the ICD-O-3 code they were
assigned. The 10167 women with other ICD-O codes, representing
5.1% of eligible subjects, were excluded from our analysis, leaving
a total of 189015 women. This group included women with
diagnoses such as Paget’s disease, because there were too few cases
with these diagnoses to evaluate them separately in our analysis. In
addition, we excluded 1116 subjects (5.9% of the total potentially
eligible subjects) because they had an unknown or missing race/
ethnicity. Since we were particularly interested in differences in ER
and PR status by histology, we also excluded 52742 cases (28.1%
of the total potentially eligible subjects) because data on their ER
and/or PR status were unknown. After these exclusions, 135157
eligible women remained, including 102463 ductal, 11275 lobular,
9636 ductal/lobular, 3248 mucinous, 2222 comedo, 2095 inflam-
matory, 1983 tubular, 1617 medullary, and 618 papillary carcinoma
cases.
In addition to histologic type, SEER registries also collect data
on other tumour characteristics including AJCC stage at diagnosis,
tumour size, lymph node status, ER and PR status, and tumour
grade. Associations between the histologic type of breast cancer
and each of these tumour characteristics were estimated using
polytomous logistic regression (Begg and Gray, 1984), and based
on likelihood ratio testing that compared models that included
and excluded the tumour characteristic of interest, each of these
tumour characteristics was statistically significant overall
(Po0.00001 for each characteristic). We stratified our main
analyses by age at diagnosis, evaluating the 100028 women
diagnosed at age 50–89 years and the 35129 women diagnosed at
age 30–49 years separately, because breast cancer risk factors,
outcomes, and tumour characteristics differ by age, and particu-
larly by menopausal status, and thus age is likely to be an
important modifier of the associations assessed here (Bernstein,
1998). In the absence of information on menstrual history, 50 years
of age has been shown to be a reasonable proxy for distinguishing
postmenopausal from premenopausal women (Morabia and
Flandre, 1992). Using Stata SE for Windows (Stata Corporation,
College Station, TX, USA) statistical software, odds ratios (OR) and
95% confidence intervals (CI) were calculated. In all analyses,
ductal carcinoma cases served as the reference histology group. All
analyses were adjusted for age at diagnosis (continuous), year of
diagnosis (continuous), SEER registry (categorical), and race/
ethnicity (categorical). In addition, our analyses of stage, tumour
size, and lymph node status were also adjusted for ER/PR status,
our analyses of ER status were also adjusted for PR status, our
analyses of PR status were also adjusted for ER status, and our
analyses of tumour grade were also adjusted for stage and ER/PR
status because each were hypothesized as potential confounders.
Age at diagnosis (categorized as 30–49 years vs 50–89 years of
age) was found to be an effect modifier of each of the relationships
we assessed based on likelihood ratio testing, since P-values for
interaction were all o0.05. In fact, all P-values for interaction were
o0.00001, except those for tumour size (P¼0.0014) and nodal
status (P¼0.0149).
Certain associations were not evaluated because the histopatho-
logic definition of certain histologic types of breast cancer is
dependent on the presence of particular clinical or pathologic
features. Specifically, inflammatory carcinoma is defined by
tumour emboli in dermal lymphatic vessels, and since 499% of
inflammatory cases included in this study were stage III or stage IV
and 98% were X5.0cm we did not evaluate stage and tumour
size differences among inflammatory cases. Also, since tubular
carcinomas are by definition well differentiated, and 99% of
tubular cases in this study were grade 1 or 2, we did not evaluate
tumour grade differences among tubular cases. Finally, since
medullary carcinomas are characteristically poorly differentiated,
and 90% of medullary cases in this study were grade 3 or 4, we did
not evaluate tumour grade differences among medullary cases.
RESULTS
Of the nine histologic types assessed, mucinous and papillary
carcinoma cases had the oldest mean ages at diagnosis (65.8 and
65.7 years, respectively) and medullary carcinoma cases had the
youngest mean age at diagnosis (52.8 years) (Table 1). While the
number of ductal, lobular, ductal/lobular, mucinous, tubular, and
inflammatory carcinoma cases increased over time, the number of
comedo and medullary carcinoma cases declined and the number
of papillary carcinoma cases held fairly constant. Variations in the
racial/ethnic compositions of cases were also observed by
histologic type.
Among women diagnosed with breast cancer at age 50–89 years
of age, women with lobular, ductal/lobular, and inflammatory
carcinoma were statistically more likely to be diagnosed with stage
III/IV disease, while mucinous, tubular, comedo, and medullary
carcinoma cases were less likely, compared to women with ductal
carcinoma (Table 2). With respect to tumour size, women with
lobular, ductal/lobular, and papillary carcinomas were more likely
to be diagnosed with tumours that were 5.0cm or larger (13.0, 7.5,
and 9.5% of these women had tumours X5.0cm, respectively)
compared to ductal carcinoma cases (5.6%), while tubular
carcinoma cases were less likely (0.8%). Lobular, ductal/lobular,
and inflammatory carcinoma cases also were more likely to be
diagnosed with node-positive disease. Alternatively, mucinous,
comedo, tubular, medullary, and papillary cases all were less
likely to be diagnosed with node-positive disease. With respect
to hormone receptor status, lobular, ductal/lobular, mucinous,
tubular, and papillary carcinoma cases were 0.2–0.4-fold less likely
to be diagnosed with ER /PR  tumours, while comedo,
medullary, and inflammatory cases were 1.7–11.6-fold more likely
to be diagnosed with ER /PR  tumours compared to ductal
carcinoma cases. Finally, compared to ductal carcinoma cases,
women with mucinous and papillary carcinomas tended to have
lower-grade tumours, while comedo and inflammatory carcinoma
cases tended to have higher-grade tumours.
Similar to the older women, among women diagnosed with
breast cancer at age 30–49 years of age, those with lobular, and
ductal/lobular carcinomas were more likely to be diagnosed with
stage III/IV disease, while mucinous, comedo, tubular, and
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with ductal carcinoma (Table 3). With respect to tumour size,
women with lobular and ductal/lobular carcinomas were more
likely to be diagnosed with tumours that were 5.0cm or larger
(18.1 and 12.1% of these women had tumours X5.0cm,
respectively) compared to ductal carcinoma cases (8.6%), while
tubular and medullary carcinoma cases were less likely (1.0 and
5.6%, respectively). Lobular, ductal/lobular, and inflammatory
carcinoma cases also were more likely to be diagnosed with node-
positive disease, and mucinous, comedo, tubular, and medullary
cases were less likely, compared to ductal cases. In addition,
lobular, ductal/lobular, mucinous, tubular, and papillary carcino-
ma cases were 0.2–0.5-fold less likely to be diagnosed with ER /
PR  tumours, while comedo, medullary, and inflammatory cases
were 1.9–15.3-fold more likely to be diagnosed with ER /PR 
tumours compared to ductal carcinoma cases. Finally, compared
to ductal carcinoma cases, women with lobular and mucinous
carcinomas tended to have lower-grade tumours, while comedo
and inflammatory carcinoma cases tended to have higher-grade
tumours.
DISCUSSION
Before interpreting the results of this study, it is important to
acknowledge its limitations. First, the histologic categorizations
used were based on diagnoses made by multiple pathologists in
multiple institutions, and diagnostic criteria may vary somewhat
by both individual pathologists and institutions, resulting in a
certain degree of misclassification error. Studies evaluating the
concordance between histologic classifications of breast tumours
ascertained by SEER registries and those made through a
centralized pathology review are needed to quantify the magnitude
of this misclassification, as none have been reported in the
literature. However, the misclassification of histologic type present
in the SEER data is likely to be nondifferential, and as a result it
may obscure differences but not lead to the identification of
spurious differences. Also encouraging is that the proportions of
cases in each histopathologic category were relatively similar
across the 11 registries included in this study. One exception
was that 10.9% of cases diagnosed in Los Angeles were ductal–
lobular, while only 2.9% diagnosed in Hawaii were ductal–lobular.
However, across the remaining nine registries, the proportions
of cases that were ductal–lobular were relatively similar.
Another concern is that we lacked information regarding certain
potential confounders, including hormonal, reproductive, anthro-
pometric, and lifestyle factors, that may be associated with both
different histologic types of breast cancer and with the different
clinical and pathologic tumour characteristics we evaluated.
However, the strengths of this study are that it is large and
population-based. Thus, it provides information on the tumour
characteristics of different histologic types of breast cancer, some
of which are quite rare, that are being observed in the general
population.
Differences between various histologic types of breast cancer
have been noted in prior studies. Two studies have explored the
age distribution of different histologic types of breast cancer and
have observed some striking differences. The first study by
Stalsberg and Thomas (1993) reported that, while the relative
frequency of ductal carcinoma is essentially constant by age, the
frequencies of papillary and mucinous carcinomas tend to increase
with age, the frequencies of medullary and inflammatory
carcinomas tend to decrease with age, and the frequencies of
lobular and tubular carcinomas increase until age 50, after which
they remain fairly constant. A recent update of age-specific rates
by histologic type observed three different age-rate patterns
(Anderson et al, 2004). Specifically, rates of ductal, lobular, and
tubular carcinomas were shown to rise sharply until age 50 and
then rise more slowly, rates of papillary and mucinous carcinomas
to rise steadily with age, and rates of medullary and inflammatory
carcinoma to increase until age 50, after which they did not
continue to rise. While this study also evaluated age-specific
Table 1 Demographic characteristics of 139310 women diagnosed with nine different histologic types of breast cancer
Ductal
(n¼102463)
Lobular
(n¼11275)
Ductal/
lobular
(n¼9636)
Mucinous
(n¼3248)
Comedo
(n¼2222)
Inflammatory
(n¼2095)
Tubular
(n¼1983)
Medullary
(n¼1617)
Papillary
(n¼618)
n % n % n % n % n % n % n % n % n %
Age at diagnosis
30–39 6911 7 225 2 428 4 119 4 234 11 190 9 42 2 249 15 21 3
40–49 20754 20 1663 15 1849 19 399 12 616 28 518 25 344 17 497 31 70 11
50–59 24501 24 2534 23 2567 27 486 15 567 26 550 26 555 28 399 25 103 17
60–69 22505 22 2792 25 2173 23 731 23 436 20 388 19 536 27 272 17 146 24
70–79 19932 20 2820 25 1932 20 1005 31 287 13 308 15 397 20 153 10 177 29
80–89 7860 8 1241 11 687 7 508 16 82 4 141 7 109 6 47 3 101 16
Mean7s.d. 59.5713.6 63.4712.7 60.1712.9 65.8713.5 55.3713.1 60.7711.7 57.0713.8 52.8712.9 65.7713.2
Diagnosis year
1992–1993 17157 17 1791 16 1209 13 524 16 800 36 338 16 239 12 424 26 118 19
1994–1995 18445 18 1975 18 1377 14 571 18 553 25 338 16 331 17 342 21 133 22
1996–1997 20464 20 2203 20 1683 18 634 20 346 16 436 21 367 19 297 18 129 21
1998–1999 23315 23 2748 24 2388 25 725 22 288 13 482 23 516 26 283 18 118 19
2000–2001 23082 23 2558 23 2979 31 794 24 235 11 501 24 530 27 271 17 120 19
Race/ethnicity
Non-Hispanic white 78748 77 9605 85 7908 82 2467 76 1568 71 1518 73 1726 87 1004 62 434 70
Black 7927 8 555 5 563 6 199 6 246 11 253 12 71 4 287 18 69 11
Asian/Pacific Islander 8745 9 484 4 534 6 363 11 238 11 124 6 93 5 127 8 68 11
Hispanic white 6693 7 614 5 603 6 212 7 161 7 185 9 91 5 188 12 44 7
American Indian 350 0.3 17 0.2 28 0.3 7 0.2 9 0.4 15 0.7 2 0.1 11 0.7 3 0.5
s.d.¼standard deviation.
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yTable 2 Relationship between breast cancer histology and tumour stage, ER/PR status, and grade among women diagnosed at 50–89 years of age
a
Ductal
(n¼74798) Lobular (n¼9387) Ductal/lobular (n¼7359) Mucinous (n¼2730) Comedo (n¼1372)
Tumour characteristic % % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage
b
I 53 44 1.0 ref 48 1.0 ref 68 1.0 ref 55 1.0 ref
II 38 43 1.5 1.4–1.6
w 44 1.4 1.3–1.4
w 28 0.6 0.6–0.7
w 39 0.8 0.8–0.9
w
III/IV 9 13 2.1 1.9–2.2
w 8 1.2 1.1–1.3
w 4 0.4 0.3–0.5
w 6 0.6 0.4–0.7
w
Tumour size (cm)
b
o2.0 61 48 1.0 ref 56 1.0 ref 65 1.0 ref 58 1.0 ref
2.0–4.9 34 39 1.6 1.6–1.7
w 36 1.3 1.2–1.4
w 30 0.9 0.8–1.0
w 36 0.9 0.8–1.0
X5.0 6 13 3.5 3.3–3.8
w 8 1.7 1.5–1.9
w 5 1.0 0.8–1.2 7 0.9 0.7–1.1
Lymph node status
b
Negative 67 65 1.0 ref 62 1.0 ref 90 1.0 ref 72 1.0 ref
Positive 33 36 1.2 1.1–1.2
w 38 1.3 1.2–1.3
w 10 0.2 0.2–0.3
w 28 0.7 0.6–0.8
w
ER
c
ER+ 78 92 1.0 ref 92 1.0 ref 96 1.0 ref 57 1.0 ref
ER  22 8 0.3 0.2–0.3
w 8 0.3 0.3–0.4
w 5 0.2 0.2–0.3
w 43 2.1 1.8–2.4
w
PR
c
PR+ 67 75 1.0 ref 78 1.0 ref 83 1.0 ref 49 1.0 ref
PR  33 25 1.1 1.1–1.2
w 22 0.9 0.8–0.9
w 17 0.8 0.7–0.8
w 51 1.3 1.2–1.5
w
ER/PR
c
ER+/PR+ 65 73 1.0 ref 77 1.0 ref 82 1.0 ref 44 1.0 ref
ER+/PR  13 20 1.3 1.2–1.3
w 15 1.0 0.9–1.0 13 0.8 0.7–0.9
w 13 1.5 1.3–1.8
w
ER-/PR+ 2 2 0.7 0.6–0.8
w 2 0.7 0.6–0.8
w 1 0.3 0.2–0.5
w 6 2.8 2.2–3.5
w
ER /PR  19 6 0.3 0.2–0.3
w 6 0.3 0.2–0.3
w 4 0.2 0.1–0.2
w 37 2.8 2.5–3.1
w
Grade
d
1 18 23 1.0 ref 19 1.0 ref 58 1.0 ref 6 1.0 ref
2 44 53 0.9 0.8–0.9
w 53 1.1 1.1–1.2
w 35 0.3 0.2–0.3
w 35 2.3 1.7–3.1
w
3 36 21 0.5 0.4–0.5
w 26 0.8 0.7–0.9
w 6 0.1 0.1–0.1
w 50 3.3 2.5–4.5
w
4 2 3 1.1 0.9–1.3 2 1.2 1.0–1.5 1 0.1 0.04–0.2
w 9 9.9 7.0–14.1
w
Inflammatory (n¼1387) Tubular (n¼1597) Medullary (n¼871) Papillary (n¼527)
% OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage
b
I 0.1 N/A
e 92 1.0 ref 40 1.0 ref 57 1.0 ref
II 0.4 8 0.1 0.1–0.2
w 56 1.5 1.3–1.7
w 35 0.9 0.7–1.1
III/IV 99 1 0.1 0.03–0.1
w 5 0.5 0.3–0.6
w 8 0.9 0.6–1.2
Tumour size, cm
b
o2.0 2 N/A
e 95 1.0 ref 42 1.0 ref 57 1.0 ref
2.0–4.9 9 4 0.1 0.1–0.1
w 53 1.6 1.4–1.8
w 33 1.1 0.9–1.3
X5.0 89 1 0.1 0.1–0.2
w 6 0.8 0.6–1.1 10 1.9 1.4–2.5
w
Lymph node status
b
Negative 9 1.0 ref 93 1.0 ref 71 1.0 ref 78 1.0 ref
Positive 91 19.3 15.2–24.6
w 7 0.2 0.1–0.2
w 29 0.7 0.6–0.8
w 22 0.6 0.5–0.7
w
ER
c
ER+ 57 1.0 ref 95 1.0 ref 27 1.0 ref 88 1.0 ref
ER  43 1.4 1.2–1.7
w 5 0.2 0.2–0.3
w 73 4.4 3.6–5.3
w 12 0.8 0.6–1.1
PR
c
PR+ 47 1.0 ref 81 1.0 ref 22 1.0 ref 82 1.0 ref
PR  53 1.2 1.0–1.4
w 19 1.0 0.8–1.1 78 2.6 2.1–3.2
w 18 0.5 0.4–0.7
w
ER/PR
c
ER+/PR+ 42 1.0 ref 79 1.0 ref 17 1.0 ref 80 1.0 ref
ER+/PR  15 1.3 1.1–1.6
w 16 1.1 0.9–1.2 10 2.8 2.2–3.7
w 8 0.5 0.3–0.6
w
ER /PR+ 5 2.0 1.5–2.7
w 2 0.7 0.5–1.1 4 5.5 3.8–7.9
w 2 0.5 0.3–1.1
ER /PR  38 1.7 1.5–1.9
w 3 0.2 0.1–0.2
w 68 11.6 9.6–13.9
w 10 0.4 0.3–0.6
w
Grade
d
1 2 1.0 ref 86 N/A
e 0 N/A
e 40 1.0 ref
2 24 1.6 1.0–2.4
w 13 11 42 0.4 0.3–0.5
w
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w 1 78 17 0.2 0.1–0.3
w
4 67 3.0 1.9–4.8
w 0 11 2 0.4 0.2–0.8
w
OR¼odds ratio, CI¼confidence interval, ER¼oestrogen receptor, PR¼progesterone receptor, N/A¼not applicable.
wPo0.05.
aThe reference histologic type for all analyses
was ductal carcinoma.
bORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity, and ER/PR status. Data on tumour size missing for 710 ductal, 130 lobular,
34 ductal/lobular, 10 mucinous, eight comedo, one tubular, three medullary, 94 inflammatory, and three papillary carcinomas. Data on lymph node status missing for 8051 ductal,
1001 lobular, 565 ductal/lobular, 464 mucinous, 136 comedo, 336 tubular, 43 medullary, 587 inflammatory, and 99 papillary carcinomas.
cORs are adjusted for age and year at
diagnosis, cancer registry, race/ethnicity, and stage. In addition, ORs for ER status are adjusted for PR status, and ORs for PR status are adjusted for ER status.
dORs are adjusted
for age and year at diagnosis, cancer registry, race/ethnicity, stage, and ER/PR status. Data on grade missing for 5732 ductal, 4149 lobular, 984 ductal/lobular, 981 mucinous, 367
comedo, 270 tubular, 321 medullary, 223 inflammatory, and 140 papillary carcinomas.
eThese ORs were not calculated because almost all inflammatory carcinomas are stage III
or IV and 45.0cm in size, almost all tubular carcinomas are well differentiated, and almost all medullary carcinomas are poorly differentiated.
Table 2 (Continued)
Inflammatory (n¼1387) Tubular (n¼1597) Medullary (n¼871) Papillary (n¼527)
Tumour characteristic % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Table 3 Relationship between breast cancer histology and tumour stage, hormone receptor status, and grade among women diagnosed at 30–49 years
of age
a
Ductal
(n¼27665) Lobular (n¼1888) Ductal/lobular (n¼2277) Mucinous (n¼518) Comedo (n¼850)
Tumour characteristic % % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage
b
I 40 36 1.0 ref 36 1.0 ref 61 1.0 ref 42 1.0 ref
II 50 48 1.2 1.1–1.4
w 52 1.3 1.2–1.4
w 35 0.5 0.4–0.6
w 49 0.8 0.7–1.0
w
III/IV 10 16 2.4 2.1–2.7
w 12 1.7 1.5–1.9
w 4 0.3 0.2–0.5
w 9 0.7 0.6–1.0
w
Tumour size (cm)
b
o2.0 49 43 1.0 ref 48 1.0 ref 59 1.0 ref 48 1.0 ref
2.0–4.9 42 39 1.3 1.2–1.4
w 40 1.1 1.0–1.2
w 34 0.8 0.6–0.9
w 41 0.9 0.8–1.0
X5.0 9 18 3.4 2.9–3.9
w 12 1.8 1.6–2.2
w 7 0.8 0.5–1.1 12 1.2 0.9–1.5
Lymph node status
b
Negative 57 54 1.0 ref 48 1.0 ref 85 1.0 ref 60 1.0 ref
Positive 43 46 1.2 1.1–1.3
w 52 1.4 1.3–1.6
w 15 0.2 0.2–0.3
w 40 0.8 0.7–1.0
w
ER
c
ER+ 66 89 1.0 ref 87 1.0 ref 91 1.0 ref 56 1.0 ref
ER  34 11 0.4 0.3–0.5
w 13 0.4 0.4–0.5
w 9 0.2 0.1–0.3
w 44 1.2 1.0–1.5
PR
c
PR+ 63 85 1.0 ref 83 1.0 ref 81 1.0 ref 54 1.0 ref
PR  38 15 0.5 0.5–0.6
w 17 0.6 0.5–0.7
w 19 1.1 0.8–1.4 46 1.3 1.0–1.5
w
ER/PR
c
ER+/PR+ 58 81 1.0 ref 80 1.0 ref 79 1.0 ref 46 1.0 ref
ER+/PR  8 8 0.7 0.6–0.8
w 8 0.6 0.5–0.8
w 12 1.1 0.9–1.5 11 1.6 1.2–2.0
w
ER /PR+ 5 4 0.6 0.5–0.8
w 3 0.5 0.4–0.7
w 2 0.3 0.2–0.6
w 8 1.6 1.2–2.1
w
ER /PR  29 7 0.2 0.1–0.2
w 10 0.2 0.2–0.3
w 7 0.2 0.1–0.3
w 36 1.5 1.3–1.7
w
Grade
d
1 10 19 1.0 ref 14 1.0 ref 45 1.0 ref 4 1.0 ref
2 37 55 0.8 0.7–0.9
w 51 1.0 0.9–1.1 41 0.3 0.2–0.4
w 28 1.7 1.1–2.6
w
3 50 22 0.3 0.3–0.4
w 32 0.6 0.5–0.7
w 13 0.1 0.1–0.1
w 57 2.5 1.7–3.8
w
4 3 3 0.7 0.5–1.0 3 0.9 0.7–1.2 1 0.1 0.03–0.3
w 11 7.2 4.5–11.7
w
Inflammatory (n¼708) Tubular (n¼386) Medullary (n¼746) Papillary (n¼91)
% OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
Stage
b
I0 N / A
e 87 1.0 ref 33 1.0 ref 42 1.0 ref
II 1 12 0.1 0.1–0.2
w 62 1.1 0.9–1.3 50 0.9 0.6–1.5
III/IV 99 1 0.03 0.01–0.1
w 4 0.3 0.2–0.5
w 9 0.8 0.4–1.8
Tumour size (cm)
b
o2.0 2 N/A
e 92 1.0 ref 34 1.0 ref 52 ref
2.0–4.9 7 7 0.1 0.1–0.2
w 60 1.4 1.2–1.7
w 36 0.8
X5.0 91 1 0.1 0.03–0.2
w 6 0.6 0.4–0.8
w 12 1.4
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separately, it did not directly compare the distributions of ER
status, or other clinical or tumour characteristics by histologic
type.
In addition, risk of mortality has been observed to vary by
histologic type as women with inflammatory breast cancers have
an increased risk of mortality compared to women with other
histologic types of breast cancer (Stierer et al, 1993; Anderson et al,
2003), while women with lobular, mucinous, comedo, tubular,
medullary, and papillary carcinomas have lower risks of mortality
compared to women with ductal carcinomas (Li et al, 2003c).
However, few previous studies have evaluated differences in
clinical and pathologic tumour characteristics by histologic
type. With respect to ER/PR status, lobular, ductal/lobular, and
mucinous carcinomas have been shown to be more likely to be
ERþ/PRþ compared to ductal carcinomas, similar to what we
observed here (Desai et al, 2000; Arpino et al, 2004; Korhonen
et al, 2004; Mathieu et al, 2004). However, studies have not
evaluated ER/PR status in rarer histologic types of breast cancer,
or evaluated differences in stage, tumour size, lymph node status,
or grade by histologic type.
Here we observed several differences in these characteristics by
histologic type, which only varied somewhat by age at diagnosis.
The primary differences seen between our groups of largely
postmenopausal women vs largely premenopausal women were
differences in magnitudes rather than directions of risk. For
example, among comedo carcinoma cases, the observed elevated
risks of ER /PR  tumours compared to ductal cases were more
pronounced among the older women (OR¼2.8) than among the
younger women (OR¼1.5). Exceptions to this were that lobular
carcinomas diagnosed among younger women were less likely to
be PR  compared to ductal cases, though this difference was not
seen among the older women. In addition, older, but not younger,
women with comedo carcinoma had an elevated risk of ER 
tumours. Finally, the higher risk of tumours X5.0cm and the
lower risk of node-positive tumours seen among older women with
papillary carcinomas were not observed among younger women
with papillary tumours. However, our ability to detect differences
among papillary cases 30–49 years of age was limited by a
relatively small sample size (n¼91).
Despite these differences, among both age groups of women,
mucinous, tubular, and papillary carcinomas generally had less
aggressive phenotypes compared to ductal carcinoma cases, as
they were each less likely to present at an advanced stage, to be
node positive, to be hormone receptor negative, and to have a high
grade. These features may explain why women with these tumours
have relatively low risks of mortality (Stierer et al, 1993; Li et al,
2003c). In contrast, inflammatory carcinomas appear to have the
most aggressive phenotype of any of the histologic types evaluated
as these tumours were more likely to be node positive, to be
hormone receptor negative, and to have a high grade. These
findings are consistent with the poorer survival rates that women
with these tumours experience, particularly for those with ER 
inflammatory carcinoma (Anderson et al, 2003; Li et al, 2003c).
Lobular, ductal/lobular, and comedo and medullary carcinomas
had mixed phenotypes. Lobular and ductal/lobular tumours
tended to be diagnosed at a more advanced stage and to be
both 45.0cm and node positive, but they were also much more
likely to be hormone receptor positive. In contrast, comedo and
medullary carcinomas were less likely to have an advanced stage at
diagnosis and to be node positive, but more likely to be hormone
receptor negative and to have a high grade. Interestingly, these
Lymph node status
b
Negative 9 1.0 ref 91 1.0 ref 69 1.0 ref 59 1.0 ref
Positive 91 12.7 9.0–17.8
w 9 0.1 0.1–0.2
w 31 0.6 0.5–0.7
w 41 0.9 0.6–1.4
ER
c
ER+ 43 1.0 ref 93 1.0 ref 14 1.0 ref 77 1.0 ref
ER  57 1.7 1.4–2.2
w 8 0.2 0.2–0.4
w 86 5.8 4.4–7.6
w 23 0.7 0.4–1.4
PR
c
PR+ 41 1.0 ref 85 1.0 ref 16 1.0 ref 75 1.0 ref
PR  60 1.1 0.9–1.4 15 0.8 0.6–1.1 84 2.5 2.0–3.2
w 25 0.7 0.4–1.3
ER/PR
c
ER+/PR+ 34 1.0 ref 82 1.0 ref 10 1.0 ref 70 1.0 ref
ER+/PR  9 1.2 0.9–1.6 10 1.0 0.7–1.4 4 3.2 2.1–4.8
w 7 0.6 0.3–1.5
ER-/PR+ 7 1.9 1.3–2.7
w 3 0.5 0.3–1.0
w 7 7.1 4.9–10.3
w 4 0.7 0.2–1.9
ER /PR  50 1.9 1.6–2.3
w 5 0.2 0.1–0.3
w 80 15.3 11.9–19.6
w 19 0.5 0.3–0.9
w
Grade
d
1 1 1.0 ref 87 N/A
e 1 N/A
e 22 1.0 ref
2 20 2.2 1.0–4.9
w 12 6 49 0.6 0.3–1.1
3 72 2.7 1.3–5.9
w 1 81 23 0.2 0.1–0.5
w
4 6 2.8 1.2–6.7
w 0 1 6 0.9 0.3–2.9
OR¼odds ratio, CI¼confidence interval, ER¼oestrogen receptor, PR¼progesterone receptor, N/A¼not applicable.
wPo0.05.
aThe reference histologic type for all analyses
was ductal carcinoma.
bORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity, and ER/PR status. Data on tumour size missing for 209 ductal, 24 lobular, 17
ductal/lobular, three mucinous, five comedo, 36 inflammatory, and one papillary carcinomas. Data on lymph node status missing for 1242 ductal, 118 lobular, 87 ductal/lobular, 28
mucinous, 54 comedo, 26 tubular, 17 medullary, 304 inflammatory, and six papillary carcinomas.
cORs are adjusted for age and year at diagnosis, cancer registry, race/ethnicity,
and stage. In addition, ORs for ER status are adjusted for PR status, and ORs for PR status are adjusted for ER status.
dORs are adjusted for age and year at diagnosis, cancer
registry, race/ethnicity, stage, and ER/PR status. Data on grade missing for 1732 ductal, 794 lobular, 289 ductal/lobular, 198 mucinous, 215 comedo, 75 tubular, 251 medullary, 102
inflammatory, and 22 papillary carcinomas.
eThese ORs were not calculated because almost all inflammatory carcinomas are stage III or IV and greater than 5.0cm in size, almost
all tubular carcinomas are well differentiated, and almost all medullary carcinomas are poorly differentiated.
Table 3 (Continued)
Inflammatory (n¼708) Tubular (n¼386) Medullary (n¼746) Papillary (n¼91)
Tumour characteristic % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
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lower risks of mortality compared to ductal carcinoma cases, as we
have reported previously (Li et al, 2003c).
Beyond differences in their histopathologic appearances, the
results of this study suggest that different histologic types of breast
cancer also differ substantially in their clinical and tumour
characteristics. Interestingly, while inflammatory carcinomas are
more likely to be characterized by poor clinical and pathologic
tumour characteristics that do translate into poorer survival rates;
lobular, ductal/lobular, comedo, and medullary carcinomas are
characterized by a mix of tumour characteristics that are
associated with both better and poorer prognoses, though previous
data indicate that women with these tumours have lower risks of
mortality than do women with ductal carcinomas (Li et al, 2003c).
Thus, the prognostic importance and utility of the clinical and
tumour characteristics evaluated here varies by histologic type.
The differences in hormone receptor status and grade that we
observed by histologic type may reflect the different aetiologies of
these tumours. Further, the differences in stage, tumour size, and
lymph node status observed here may reflect differences in the
utility of screening approaches to detect different histologic types
of cancer. For example, it is well known that lobular tumours are
more difficult to detect with mammography compared to ductal
tumours, and this is thought to be primarily due to the fact that
lobular tumours tend to grow as linear strands or sheets of cancer
cells rather than as more discrete masses, explaining why they are
more likely to be diagnosed at a more advanced stage (Davis et al,
1979; Dixon et al, 1982; Silverstein et al, 1994; Yeatman et al, 1995).
Thus, currently, available breast cancer screening tools appear to
be relatively less or relatively more effective in detecting different
histopathologic types of breast cancer.
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